↓ Cooling
Business
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics reports that its nanobody drug, sonelokimab, successfully met all clinical endpoints in a Phase 3 trial for psoriatic arthritis.